|
Sanchez-Canovas M, Jimenez-Fonseca P, Fernandez Garay D, Cejuela Solis M, Casado Elia D, Coma Salvans E, de la Haba Vacas I, Gomez Sanchez D, Fernandez Montes A, Morales Gimenez R, Biosca Gomez de Tejada M, Arrazubi Arrula V, Sequero Lopez S, Otero Candelera R, Sanchez Cendra C, Justo de la Pena M, Moreno Munoz D, Orillo Sarmiento M, Martinez de Castro E, Garcia Escobar I, Bernal Vidal A, Ortega Moran L, Munoz Martin AJ, Sanchez Bayona R, Martinez Ortiz MJ, Ayala de la Pena F, Vicente V, Carmona-Bayonas A. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study. PLoS One. 2023 May 9;18(5):e0266305. doi: 10.1371/journal.pone.0266305. eCollection 2023. PubMed PMID: 37159465; PubMed Central PMCID: PMC10168567.
AÑO: 2023; IF: 2.9
|
37159465
|
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 3.9
|
|
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macia-Rivas L, Arrazubi V, Cacho Lavin D, Hernandez San Gil R, Custodio A, Cano JM, Fernandez Montes A, Mirallas O, Macias Declara I, Vidal Tocino R, Visa L, Limon ML, Pimentel P, Martinez Lago N, Sauri T, Martin Richard M, Mangas M, Gil Raga M, Calvo A, Reguera P, Granja M, Martin Carnicero A, Hernandez Perez C, Cerda P, Gomez Gonzalez L, Garcia Navalon F, Pacheco Barcia V, Gutierrez Abad D, Ruiz Martin M, Weaver J, Mansoor W, Gallego J. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157641. doi: 10.1177/17588359231157641. eCollection 2023. PubMed PMID: 36895850; PubMed Central PMCID: PMC9989382.
AÑO: 2023; IF: 4.3
|
|
Zaragoza-Huesca D, Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Pena-Garcia J, Espin S, Ricote G, Nieto A, Garcia-Molina F, Vicente V, Lozano ML, Carmona-Bayonas A, Mulero V, Perez-Sanchez H, Martinez-Martinez I. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. Biomed Pharmacother. 2023 Dec;168:115814. doi: 10.1016/j.biopha.2023.115814. Epub 2023 Oct 31. PubMed PMID: 37918256.
AÑO: 2023; IF: 6.9
|
|
Carmona-Bayonas A, Jimenez-Fonseca P, Gallego J, Msaouel P. Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries. Cancer Invest. 2022 Jan;40(1):1-13. doi: 10.1080/07357907.2021.1999971. Epub 2021 Nov 25. PubMed PMID: 34709109.
AÑO: 2022; IF: 2.4
|